How Okta, IBD Stock Of The Day, Is Targeting 'Nonhuman' Identity Opportunity

Okta Cl A Okta Cl A OKTA $ 147.56 $4.05 2.82% 28% IBD Stock Analysis Stock bouncing off 21-day after rebounding from 10-week OKTA may be working on new base IBD Composite Rating 98/99 Industry Group Ranking 4/197 Emerging Pattern Pullback Pullback A stock may pull back after a breakout, often to the 50-day line. A rebound from the first…